Tissue Regenix Group PLC Resolution of Cyber Security Incident (9167B)
February 04 2020 - 6:47AM
UK Regulatory
TIDMTRX
RNS Number : 9167B
Tissue Regenix Group PLC
04 February 2020
This announcement contains inside information
Tissue Regenix Group plc
Resolution of Cyber Security Incident
Leeds, 4 February 2020 - Tissue Regenix Group (AIM:TRX) ("Tissue
Regenix" or the "Company") the regenerative medical devices
company, is pleased to confirm that due to actions taken following
the cyber security incident, as originally reported by the Company
on 28 January 2020, the recovery has now been completed and all
critical IT systems have been restored and brought back online. All
processing in the Company's United States facility has also resumed
with immediate effect.
The incident is projected to have a very short-term impact on
the Company's ability to service customer demand, and it is
anticipated that delayed orders will be dispatched over the coming
weeks. Based on the Company's initial investigations, there are no
indications of any external transfer of sensitive or financial
data, and the Company does not expect any associated costs of the
system restoration to be material to the short-term cash flow.
The Company has implemented additional data security procedures
to reduce the risk of future similar incidents from occurring, and
will review its IT security procedures and service providers on an
ongoing basis moving forward.
The person responsible for this announcement is John Samuel,
Executive Chairman.
For more Information:
Tissue Regenix Group plc Tel: 0330 430 3073
Caitlin Pearson Head of Communications
--------------------------------------------- --------------------
Stifel Nicolaus Europe Limited (Nominated Tel: 0207 710 7600
Adviser and Broker)
Jonathan Senior / Alex Price / Ben Maddison
--------------------------------------------- --------------------
FTI Consulting Tel: 0203 727 1000
Simon Conway / Victoria Foster Mitchell
/ Mary Whittow
============================================= ====================
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. Tissue Regenix was formed in 2006 when it
was spun-out from the University of Leeds, UK. The company's
patented decellularisation ('dCELL(R) ') technology removes DNA and
other cellular material from animal and human soft tissue leaving
an acellular tissue scaffold which is not rejected by the patient's
body and can then be used to repair diseased or worn out body
parts. Current applications address many critical clinical needs
such as sports medicine, heart valve replacement and wound
care.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.',
January 2016 saw the establishment of joint venture GBM-V, a multi-
tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies(R)
, a biotech company that specializes in regenerative medicine and
is dedicated to the development of innovative osteoinductive and
wound care scaffolds that enhance healing opportunities of defects
created by trauma and disease. CellRight's human osteobiologics may
be used in spine, trauma, general orthopedic, foot & ankle,
dental, and sports medicine surgical procedures.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCFZGGZMDKGGZM
(END) Dow Jones Newswires
February 04, 2020 06:47 ET (11:47 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Sep 2023 to Sep 2024